We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Invited Commentary |

Bone Density and Bone Turnover Marker Monitoring After Discontinuation of Alendronate Therapy An Evidence-Based Decision to Do Less

Margaret L. Gourlay, MD, MPH1; Kristine E. Ensrud, MD, MPH2,3,4
[+] Author Affiliations
1Department of Family Medicine, University of North Carolina, Chapel Hill
2Department of Medicine, University of Minnesota Medical School, Minneapolis
3Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis
4Department of Medicine, Minneapolis VA Health Care System, Minneapolis, Minnesota
JAMA Intern Med. 2014;174(7):1134-1135. doi:10.1001/jamainternmed.2014.162.
Text Size: A A A
Published online


The clinical utility of medication monitoring has been a controversial issue in osteoporosis management. In the 19981 and 20012 coverage rules commonly called the “Bone Mass Measurement Act,” the Centers for Medicare & Medicaid Services (CMS) outlined provisions for bone mineral density (BMD) and bone turnover marker measurements for Medicare beneficiaries. The CMS covers BMD testing for 5 indications and bone turnover marker testing for 3 indications (Box), including monitoring of US Food and Drug Administration–approved osteoporosis drug therapy. The CMS authorizes BMD measurements if at least 23 months have passed since the last measurement, or more frequently “when medically necessary.”1(p34324) The CMS also summarized appropriate use of bone turnover markers, assuming documentation of medical necessity: “because of significant specimen to specimen collagen crosslink physiologic variability (15-20%), current recommendations for appropriate utilization include: one or two base-line assays from specified urine collections on separate days; followed by a repeat assay about three months after starting anti-resorptive therapy; followed by a repeat assay in 12 months after the three-month assay; and thereafter not more than annually, unless there is a change in therapy in which circumstance an additional test may be indicated three months after the initiation of new therapy.”2(p58844)

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles